Researchers have identified a new strategy for potentially treating a subset of intractable cancers by decoupling the entire RAS / MAP Kinase signaling pathway from external growth signals.
A comprehensive genetic analysis of metastatic prostate cancer has, for the first time, revealed a number of major ways in which abnormal alterations of the genome propel this aggressive form of the disease.
Study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that about 17 percent of these cancers belong to a deadlier subtype of metastatic prostate cancer.
UC San Francisco researchers have discovered a promising new line of attack against lethal, treatment-resistant prostate cancer.
In older men who survived low-risk cancer and have limited life expectancy, frequent PSA screenings may do more harm than good
Treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy.
Cancer specialists from UCSF will present new findings at the annual meeting of the American Society of Clinical Oncology (ASCO), the world’s largest clinical cancer research meeting.
A test commonly used in breast cancer has been found to also identify which patients with aggressive prostate cancer will benefit from hormonal therapy.
A new study identified genetic predictors of normal prostate-specific antigen (PSA) levels in healthy men, which could be used to improve the accuracy of PSA-based prostate cancer screening tests.